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Purpose: As changes in antibiotic therapy are common, intent‐to‐treat and
definitive therapy exposure definitions in infectious disease clinical trials and observa-
tional studies may not accurately reflect all antibiotics received over the course of the
infection. Therefore, we sought to describe changes in antibiotic therapy and unique
treatment patterns among patients with bacteremia.
Methods: We conducted a retrospective cohort study of hospitalizations from
Veterans Affairs (VA) Medical Centers (January 2002‐September 2015) and commu-
nity hospitals (de‐identified Optum Clinformatics DataMart with matched Premier
Hospital data; October 2009‐March 2013). In the VA population, antibiotic exposures
were mapped from the culture collection date among those with positive Staphylococ-
cus aureus cultures. In the Optum‐Premier population, exposures were mapped from
the admission date among those with a primary diagnosis of bacteremia.
Results: Our study included 50 467 bacteremia admissions, with only 14% of
admissions having the same treatment pattern as another admission. For every 100
bacteremia admissions, 89 had changes in antibiotic therapy. For every 100
bacteremia admissions with changes in therapy, 95 had unique antibiotic treatment
patterns. These findings were consistent in both populations, over time, and among
different facilities within study populations. The median time to first therapy change
was 2 days after initial therapy, with a median of three changes.
Conclusions: Changes in antibiotic therapy for bloodstream infections were nearly
universal regardless of hospital setting. Based on our findings, common antibiotic
exposure definitions of intent‐to‐treat and definitive therapy would misclassify
exposure in 86% of admissions, which highlights the need for better operational
definitions of exposure in infectious diseases research.
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1 | INTRODUCTION
Serious infections, such as drug‐resistant bloodstream infections, have
become increasingly complicated to treat.1,2 Initial treatment decisions
are often made without knowledge of the infecting organism(s) and in
the absence of a confirmed source of infection.1 Management of these
patients is challenging as bloodstream infections are associated
with high mortality rates, and evidence suggests that immediate treat-
ment with appropriate therapies can significantly improve survival.1,3,4
However, further complicating these decisions are the lack of real‐world
evidence regarding the most effective and safe treatment approaches,
including which antibiotics to use and their duration of use.5,6
The complex treatment regimens used to treat infectious diseases,
which consist of relatively short exposure periods and multiple
changes in therapy, create great difficulty in accurately defining antibi-
otic exposures for the evaluation of clinical success. Often, patients
are started on empiric broad‐spectrum antibiotics for a suspected
infection.1,7 This therapy may be continued for 1 to 5 days, depending
on whether rapid diagnostics are available, when clinical culture
results are received, and if/when infectious disease clinicians become
involved. Once culture results are available, patients should be
switched to targeted or definitive therapy based on the infecting
organism and related susceptibilities.8 However, some may be contin-
ued on broad‐spectrum therapy. Other changes may be made in prep-
aration for hospital discharge, where intravenous therapy is switched
to oral therapy, or cases of insufficient clinical response. Combination
therapy regimens further complicate efforts to measure antimicrobial
exposures due to potential additive or synergistic effects. As the spec-
trum of common antibiotic regimens and real‐world patterns of treat-
ment for serious infections have yet to be described, the objective of
this study was to map all antibiotic exposures for those with bacter-
emia. As treatment practices may vary by health system, we included
both Veterans Affairs (VA) Medical Centers (VAMCs) and community
hospitals in our study. Further, treatment practices will vary by
causative organism; therefore, we included both an organism‐specific
cohort and a disease‐state cohort.
2 | METHODS
We utilized two data sources for this retrospective cohort study, the
national VA databases and a de‐identified Clinformatics DataMart
(OptumInsight, Eden Prairie, Minnesota) with matched Premier
Hospital data. In the VA population, we included hospital inpatients
with positive blood cultures for Staphylococcus aureus (methicillin‐
susceptible [MSSA] and methicillin‐resistant [MRSA]) between 1
January 2002 and 30 September 2015. In the Optum‐Premier
population, patients were included if they were hospitalized between
1 October 2009 and 31 March 2013 with a primary diagnosis of
bacteremia or septicemia (International Classification of Diseases,
Ninth Revision, Clinical Modification [ICD‐9‐CM] codes 003.1, 020.2,
022.3, 036.2, 038.0, 038.1, 038.10‐038.12, 038.19, 038.2, 038.3,
038.40‐038.44, 038.49, 038.8, 038.9, 054.5, 449, 771.81, 995.91,
995.92, 790.7) by any causative organism.9 As microbiological culture
results were not available in the Optum‐Premier data, three additional
inclusion criteria were applied: (1) at least 6 months of baseline
eligibility without a primary diagnosis of bacteremia or septicemia,
(2) initiation of antibiotic(s) on the day of admission or the day after
admission, and (3) at least two consecutive days of antibiotic therapy
within the first 3 days of the admission. For both cohorts, only adults
(age ≥ 18 y) were selected for inclusion and multiple admissions were
included if the subsequent admission date was more than 30 days
from the previous discharge date.
In the VA population, the index date was the culture collection
date. In the Optum‐Premier population, the index date was the admis-
sion date as culture data were not available. Daily antibiotic exposures
were mapped from the culture collection date until discharge. For
admissions with greater than 30 days between the index and
discharge dates, only the first 30 days were included. VA pharmacy
data included barcode medication administration records and phar-
macy dispensings. Optum‐Premier pharmacy data were ascertained
from inpatient hospital charge records.
Changes in therapy were identified and summed per patient. The
median time to first change was calculated for those with changes
in therapy. Treatment patterns were defined from both antibiotic
exposures and duration of exposure. Dose changes and changes from
intravenous to oral forms of the same antibiotic were not considered
changes in therapy. Unique treatment patterns were defined as those
where a single admission had a specific pattern of antibiotic exposures
and durations and no other admission shared the same pattern. Non-
unique treatment patterns were defined as those where multiple
admissions had the same pattern of antibiotic exposures and dura-
tions. For example, the following was a treatment pattern shared by
several admissions, vancomycin and piperacillin‐tazobactam for 4 days,
with a switch to vancomycin alone for 3 days, while the following was
a unique treatment pattern observed in a single admission, vancomy-
cin and piperacillin‐tazobactam for 4 days, with a switch to vancomy-
cin alone for 2 days, with a switch to nafcillin for 3 days.
Trends in treatment pattern heterogeneity over time were
assessed with joinpoint regression (Joinpoint Regression Program ver-
sion 4.6.0.0; National Cancer Institute, Bethesda, Maryland). Further,
we conducted two sensitivity analyses, one in which we revised the
exposure mapping definition to account for holds of 1 day, where
one or more therapies were held for a single day and resumed the
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following day, and wider dosing frequencies (ie, every 48 h). As such,
holds, extended dosing, and 1‐day gaps were not counted as changes
in therapy in this sensitivity analysis. In the second sensitivity analysis,
unique patterns were assessed only for antibiotic exposures and did
not account for days of therapy that allowed us to assess treatment
strategies rather than day‐specific patterns.
As heterogeneity of antibiotic treatments for bacteremia may vary
by length of stay, mortality, infection source, and causative organism,
we conducted several stratified analyses. For example, we would
expect greater homogeneity in treatment patterns during shorter
hospital stays, as well as with specific infection sources or causative
organisms, whereas heterogeneity may be greater among those who
die during the admission. We therefore assessed unique antibiotic
treatment patterns stratified by length of stay, osteomyelitis (VA
population only and diagnosis code present during the admission),
inpatient mortality, and methicillin susceptibility of S aureus (VA
population only).7 Length of stay was stratified at 7 days and also by
median length of stay in each setting (Table 1).
3 | RESULTS
We identified 50 467 bacteremia admissions (47 584 VA, 2883
Optum‐Premier; Table 1). The VA population was older (median age
64 versus 58 y) and mostly male (97.7% versus 51.2%) compared with
the Optum‐Premier population. Further, the VA population had a
greater comorbidity burden (median Charlson comorbidity index 3
versus 2), longer length of stay (median 11 versus 5 d), and higher
inpatient mortality rate (17.9% versus 6.6%).
Rates of therapy changes were similar in both populations as
shown inTable 1 (88.7% VA, 84.5% Optum‐Premier). The median time
to first therapy change was 2 days after the initial therapy in both the
VA and Optum‐Premier populations. The median number of changes
was three for the VA population and two for the Optum‐Premier
population. The number of unique change patterns per the number
of admissions with changes in therapy was also similar in both popula-
tions (94.3% VA, 97.5% Optum‐Premier). Heterogeneous (unique)
treatment patterns were observed in 86.3% of the VA population
and 88.6% of the Optum‐Premier population (overall 86.4%). These
findings were consistent over time (Figure 1) and between facilities
(Figures 2 and 3). Although heterogeneity increased significantly
between 2002 and 2005 (annual percent change 2.3%, P < 0.05) in
the VA population, it remained stable thereafter (P = 0.3).
Among admissions with changes in therapy, vancomycin and
piperacillin‐tazobactam were the most commonly identified antibiotics
within treatment patterns for both study populations (Figure 4).10
Some variation was observed between settings in the percentage of
patterns with a specific antibiotic, such as with vancomycin (92.5%
VA, 65.6% Optum‐Premier), which was expected since the VA study
population included patients with S aureus bacteremia while the
Optum‐Premier population included those with diagnoses of
bacteremia caused by any organism. Alternatively, utilization was
similar for other antibiotics, such as with piperacillin‐tazobactam
(45.3% VA, 46.4% Optum‐Premier) and ciprofloxacin (20.5% VA,
19.2% Optum‐Premier).
Greater variation in unique treatment patterns between the study
populations was observed for admissions without changes in therapy
(22.7% VA, 40.1% Optum‐Premier). Among admissions without
changes in therapy, vancomycin was the most commonly identified
antibiotic within treatment patterns in the VA population (60.1%),









Age, median (IQR) 64 (57‐75) 58 (48‐65)
Male, no. (%) 46 509 (97.7%) 1476 (51.2%)
Charlson comorbidity index,
median (IQR)
3 (2‐5) 2 (0‐3)
Length of stay, d, median (IQR) 11 (6‐20) 5 (3‐9)
Inpatient mortality, no. (%) 8504 (17.9%) 191 (6.6%)
Change in therapy
Number with change, no. (%) 42 220 (88.7%) 2437 (84.5%)
Day of change, median (IQR) 2 (1‐3) 2 (2‐3)
Number of changes,
median (IQR)
3 (2‐6) 2 (1‐4)
Unique patterns, no. (%) 39 825 (94.3%) 2375 (97.5%)
No change in therapy
Number without change,
no. (%)
5364 (11.3%) 446 (15.5%)
Unique patterns, no. (%) 1218 (22.7%) 179 (40.1%)
Overall heterogeneity 41 043 (86.3%) 2554 (88.6%)
43 597 (86.4%)
Abbreviations: IQR, interquartile range; no., number. Unique patterns indi-
cate those where a single admission had a specific pattern of antibiotic
exposures and durations and no other admission shared the same pattern.
KEY POINTS
• Among more than 50 000 bacteremia admissions,
antibiotic treatment was highly heterogeneous in two
distinct study populations, over time, and among
different facilities within each study population.
• Changes in antibiotic therapy occurred in 89% of
admissions (median of three changes over course of
treatment), with 95% having unique treatment patterns.
• Common antibiotic exposure definitions of intent‐to‐
treat and definitive therapy would misclassify exposure
in 86% of the study population, which highlights the
need for better operational definitions of exposure in
infectious diseases research.
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while ceftriaxone (28.3%) was the most common antibiotic in the
Optum‐Premier population (Figure 5).10 The second most common
antibiotic was piperacillin‐tazobactam in the VA population (22.5%)
and vancomycin (20.2%) in the Optum‐Premier population.
Common treatment patterns among admissions both with and
without changes in therapy differed between the study populations.
The top 250 treatment patterns (sorted by count, then alphabetically)
for each population, with at least four observations per pattern, can be
found in Tables S1.1 to S1.4. In the VA population, combination
therapy with piperacillin‐tazobactam and vancomycin for various
durations, with a change to either vancomycin monotherapy or
piperacillin‐tazobactam monotherapy for various durations, was
FIGURE 1 Antibiotic treatment patterns by year. Veterans Affairs (VA) Medical Centers are represented with solid bars, and Optum‐Premier are
represented with lined bars. Unique patterns indicate those where a single admission had a specific pattern of antibiotic exposures and durations
and no other admission shared the same pattern. Common patterns indicate those where multiple admissions had the same pattern of antibiotic
exposures and durations. In the VA population, a significant increase in heterogeneity was observed between 2002 and 2005 (annual percent
change 2.3%, P < 0.05); however, heterogeneity remained stable thereafter (P = 0.3) [Colour figure can be viewed at wileyonlinelibrary.com]
FIGURE 2 Antibiotic treatment patterns by facility, Veterans Affairs Medical Centers. Unique patterns indicate those where a single admission
had a specific pattern of antibiotic exposures and durations and no other admission shared the same pattern. Common patterns indicate those
where multiple admissions had the same pattern of antibiotic exposures and durations. Excluding 14 facilities with less than 20 admissions [Colour
figure can be viewed at wileyonlinelibrary.com]
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among the common patterns observed (Table S1.1). Monotherapy,
with either vancomycin or piperacillin‐tazobactam, along with combi-
nation therapy of the two, was the common treatment observed
among those without changes in therapy (Table S1.2). In Optum‐
Premier, the top 10 patterns included seven different antibiotics
(Table S1.3). Monotherapy, with either vancomycin or levofloxacin,
was the common treatment observed among those without changes
in therapy (Table S1.4). Duration of antibiotic therapy was 4 days or
less among the top five patterns in each population (Tables S1.1‐
S1.4). While changes in therapy were slightly lower when accounting
for holds, extended dosing, and 1‐day gaps (Table S1.5; 87.5% VA,
84.5% Optum‐Premier), proportions of unique patterns were similar
(93.9% VA, 97.0% Optum‐Premier).
In stratified analyses by length of stay, heterogeneity was lower
in shorter hospital stays, although it still exceeded 70% in shorter
stays and was greater than 90% in longer stays (Tables S1.6‐S1.7;
≤ median length of stay as noted in Table 1, 78.9% VA, 80.6%
Optum Premier, > median length of stay as noted in Table 1,
95.7% VA, 98.9% Optum‐Premier; ≤ 7 days length of stay, 73.4%
VA, 84.0% Optum‐Premier, > 7 days length of stay, 93.9% VA,
99.8% Optum‐Premier). Heterogeneity was high in patients with a
concomitant diagnosis of osteomyelitis (Table S1.8; 94.5%). In the
VA population, heterogeneity was similar in stratified analyses by
inpatient mortality (Table S1.9; inpatient mortality 84.8%, survival
87.8%); however in the Optum‐Premier population, heterogeneity
was higher among those who died during the admission than among
those who survived (95.8% and 88.4%). Heterogeneity was also
similar by methicillin susceptibility (Table S1.10; 88.7% MSSA,
84.8% MRSA).
In sensitivity analyses evaluating unique antibiotic treatment
strategies without length of therapy, among admissions with changes
in therapy, the proportion with unique patterns remained high
(Table S2.1; 78.0% VA, 87.7% Optum‐Premier; overall heterogeneity
70.3% VA, 76.8% Optum‐Premier). In the VA and Optum‐Premier
FIGURE 3 Antibiotic treatment patterns by
facility, Optum‐Premier. Unique patterns
indicate those where a single admission had a
specific pattern of antibiotic exposures and
durations and no other admission shared the
same pattern. Common patterns indicate
those where multiple admissions had the
same pattern of antibiotic exposures and
durations. Excluding 269 facilities with less
than 10 admissions [Colour figure can be
viewed at wileyonlinelibrary.com]
FIGURE 4 Changes in therapy: utilization of specific antibiotics within treatment patterns. Percentages indicate number of treatment patterns
that included that specific antibiotic per number of bacteremia admissions (Veterans Affairs [VA] Medical Centers n = 42 220, Optum‐Premier
n = 2437) [Colour figure can be viewed at wileyonlinelibrary.com]
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populations, combination therapy with piperacillin‐tazobactam and
vancomycin with a change to vancomycin monotherapy occurred in
1.4% and 0.49% of admissions, respectively (Tables S2.2 and S2.4).
Alternatively, common treatment patterns among admissions without
changes in therapy were similar between the study populations
(Tables S2.3 and S2.5): vancomycin monotherapy (29.1% VA, 4.7%
Optum‐Premier), combination therapy with piperacillin‐tazobactam
and vancomycin (11.0% VA, 5.4% Optum‐Premier), and piperacillin‐
tazobactam monotherapy (4.7% VA, 10.1% Optum‐Premier). Hetero-
geneity was again higher in longer hospital stays (Tables S2.7‐S2.8)
and among those who died during the admission in the Optum‐
Premier population (Table S2.9; 92.7%).
4 | DISCUSSION
To our knowledge, this is the first study to describe the full spectrum
of real‐world treatment patterns for bacteremia in two national
cohorts. Exposure mapping has traditionally been applied in adherence
research, specifically to long‐term treatments for chronic diseases,
such as diabetes or hypercholesterolemia.11 By creating drug treat-
ment maps for each patient on each day of the observation period,
adherence research is able to calculate exposure measures such as
proportion of days covered, medication possession ratio, and gaps in
therapy.11,12 Using this approach, we were able to identify changes
in antibiotic therapy and unique patterns of antibiotic treatments.
For every 100 bacteremia admissions, 89 had changes in antibiotic
therapy, and for every 100 bacteremia admissions with changes in
therapy, 95 had different antibiotic treatment patterns. Heteroge-
neous treatment patterns were identified in 86 of every 100 bacter-
emia admissions.
Interestingly, the observed heterogeneity in treatment patterns
persisted over time was consistent in the clinically distinct study pop-
ulations and was similar among different facilities within each study
population. With the release of MRSA treatment guidelines in 2011,
we expected a change in unique patterns; however, heterogeneity
remained stable in subsequent years.7 When considering unique pat-
terns collectively among those with and without changes in therapy,
variability exceeded 90% even among the facilities with the lowest
percentage of unique patterns.
We did expect to observe greater homogeneity in treatment
patterns in the VA study population for three reasons: (1) We
included admissions with a specific infection type (bacteremia)
caused by a specific organism (S aureus) that was confirmed from
positive blood cultures, (2) these were admissions from a closed
health care system, and (3) the study population tends to be more
homogenous in terms of patient characteristics. We also expected
to observe greater heterogeneity in the Optum‐Premier population
since we included admissions with diagnoses of bacteremia caused
by any organism. While heterogeneity could be interpreted as higher
than expected in the VA and perhaps lower than expected in
Optum‐Premier, heterogeneity was high in both groups (86.3% VA,
88.6% Optum‐Premier).
Total duration of antibiotic exposure was low among the common
patterns, indicating that these common patterns were observed
among patients who were discharged soon after culture/admission.
We did not assess postdischarge outpatient antibiotic treatments as
we were specifically interested in inpatient treatment patterns. Had
we included the full duration of treatment, which would have been a
minimum of 2 weeks for S aureus bacteremia and may include
postdischarge changes to oral or outpatient parenteral antibiotic
therapy to facilitate hospital discharge, heterogeneity likely would
have been even greater.7 Further, in assessing treatment strategies
that did not account for days of therapy, heterogeneity still exceeded
70%. Interestingly, heterogeneity remained high in shorter hospital
stays, exceeding 70%, by inpatient mortality and methicillin suscepti-
bility, exceeding 80% in all groups, and in a single infection source
(osteomyelitis), exceeding 90%. Although we expected heterogeneity
FIGURE 5 Without changes in therapy: utilization of specific antibiotics within treatment patterns. Percentages indicate number of treatment
patterns that included that specific antibiotic per number of bacteremia admissions (Veterans Affairs [VA] Medical Centers n = 5364, Premier‐
Optum n = 446) [Colour figure can be viewed at wileyonlinelibrary.com]
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to be somewhat higher with MRSA than MSSA, MSSA treatment
heterogeneity was actually slightly higher (88.7% MSSA, 84.8%
MRSA).
In infectious diseases research, antibiotic exposure definitions tend
to be overly broad and may not accurately reflect the full spectrum of
treatment. In both clinical trials and observational studies, these
oversimplified definitions lead to misclassification by considering
certain periods of treatment as ignorable. Such ignorable periods
therefore assume equivalence of efficacy/effectiveness between all
other antibiotics utilized in the treatment of that infection and for
any duration. For example, intent‐to‐treat does not take into account
concomitant or subsequent exposures after randomization. As such, in
clinical trials that allow for adjunctive therapy and changes in
therapy, postrandomization antibiotics are treated as ignorable.5,6,13-
19 Additionally, antibiotic therapy prior to randomization may also be
treated as ignorable, and despite randomization, exposures may differ
significantly between study populations.5,14,16-19 It is difficult to
assess the impact of therapy prior to randomization, adjunctive
therapy, or changes in therapy without explicit reporting in trial
results and sensitivity analyses assessing the impact of these other
antibiotic exposures.
In observational research, definitive therapy is a common exposure
definition, which identifies treatment after a certain time point, for
example, after culture results are available.20-23 Periods treated as
ignorable may include either empiric or definitive therapy, or both,
where previous and subsequent treatments are not assessed, not
reported, and/or not controlled for.20-23 This approach assumes that
any other antibiotics received, for any duration, are equal in terms of
beneficial and harmful effects. Operational definitions of definitive
therapy also differ by study, where periods of empiric and definitive
therapy may vary between patients20,22 or be set equal for all
patients.21,24 A solution to this misclassification has been to include
those without changes in therapy, treated with monotherapy or simple
combinations. However, as our study demonstrates, these patterns are
uncommon in real‐world clinical practice.
As re‐evaluation of antibiotic therapy is a core element of antimi-
crobial stewardship, we expected to see high rates of therapy
changes.8 However, we did not expect such extensive heterogeneity
in real‐world treatment patterns. It is unclear whether the variability
in treatment approaches for the same infection represents the
forefront of individualized medicine, where each host‐organism
relationship is unique and requires a distinct approach to treatment,
or, alternatively, whether the variability results from a lack of quality
evidence supporting specific treatment regimens, particularly specific
antibiotics for specific durations.
To avoid inaccurate exposure definitions in infectious disease
research, there are several solutions for handling these traditionally
ignored exposure periods. First, clinical trials could be designed so
that randomization accounts for empiric therapy. Second, sensitivity
analyses could be conducted in clinical trials and observational
studies that control for differences in empiric therapy prior to
randomization/definitive therapy, as well as differences in antibiotic
exposures after randomization/definitive therapy. Third, time‐varying
methods could be used to account for both time‐varying antibiotic
exposures and time‐varying outcomes. Fourth, highly specific opera-
tional exposure definitions could be used in observational research,
where study populations are restricted to patients with similar
exposure patterns as identified from daily exposure mapping. The
addition of any of these approaches would provide a more accurate
description of the relationship between treatment and the clinical
outcomes being assessed.
5 | LIMITATIONS
The main limitation of the study was the use of diagnosis codes to
identify bacteremia in the Optum‐Premier population. Treatment
patterns will vary by causative organism; however, microbiology data
were not available from the data source. Bacteremia diagnosis codes
have demonstrated varying sensitivity and positive predictive value
for positive blood cultures.25 However, we observed similar heteroge-
neity in prescribing patterns and related implications on characterizing
treatment effects between our culture‐confirmed bacteremia popula-
tion and the population identified from diagnosis codes. Second, we
did not assess antibiotic dose. Had we included dose, we expect that
variability in antibiotic patterns would be close to 100%. Third, we
did not exclude patients with concomitant infections, and therefore,
some of the antibiotic exposures may have been targeting other
infecting organisms. Fourth, we did not evaluate heterogeneity in
treatment patterns by patient characteristics, such as age and comor-
bidity burden. However, since heterogeneity was high in the overall
populations, it would have also been within patient subgroups. Lastly,
we did not assess postdischarge antibiotic treatments. Therefore, if a
switch to oral therapy occurred prior to discharge, it was captured in
the pattern. However, if the prescription was dispensed after the
discharge date, it was not captured as part of the pattern. The
generalizability of this study is limited to the two national cohorts
included, patients admitted to VAMCs and patients from the Optum
Clinformatics database admitted to Premier community hospitals.
6 | CONCLUSIONS
Changes in antibiotic therapy for bloodstream infections were nearly
universal in both VAMCs and community hospitals. Common treat-
ment approaches, consisting of homogenous (nonunique) treatment
patterns, were used in only 14% of bacteremia admissions. This het-
erogeneity in antibiotic treatment patterns was consistent over time
and was similar among different facilities within each study popula-
tion. Our findings highlight the challenges of evidence‐based research
for the treatment of infectious diseases. Since so few patients receive
the same regimen, true head‐to‐head comparisons may not be
possible due to small numbers and therefore rely on overly broad
definitions. As antibiotic exposure definitions are unlikely to be as
accurate as previously assumed, noninferiority, superiority, compara-
tive effectiveness, and comparative safety studies in infectious
diseases should be interpreted with caution.
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